Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small ...

Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer  AstraZeneca

FLUMIST® (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now av...

FLUMIST® (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now available for home delivery  AstraZeneca

Tezspire approved in the US for chronic rhinosinusitis with nasal polyps - AstraZeneca

Tezspire approved in the US for chronic rhinosinusitis with nasal polyps  AstraZeneca

Advancing data and artificial intelligence - AstraZeneca

Advancing data and artificial intelligence  AstraZeneca

VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extra...

VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH  AstraZeneca

Transforming long-term outcomes in prostate cancer - AstraZeneca

Transforming long-term outcomes in prostate cancer  AstraZeneca

Leading the revolution in pancreatic cancer - AstraZeneca

Leading the revolution in pancreatic cancer  AstraZeneca

Tezspire recommended for approval in the EU by CHMP for chronic rhinosinusitis with nasal polyps ...

Tezspire recommended for approval in the EU by CHMP for chronic rhinosinusitis with nasal polyps  AstraZeneca

Camizestrant demonstrated highly statistically significant and clinically meaningful improvement ...

Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 Phase III trial  AstraZeneca

Calquence plus chemoimmunotherapy approved in the US for patients with previously untreated mantl...

Calquence plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma  AstraZeneca

AstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and man...

AstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beijing  AstraZeneca

AstraZeneca announces collaboration and investment agreement with Cellectis to accelerate cell th...

AstraZeneca announces collaboration and investment agreement with Cellectis to accelerate cell therapy and genomic medicine ambitions  AstraZeneca

AstraZeneca to acquire CinCor Pharma to strengthen cardiorenal pipeline - AstraZeneca

AstraZeneca to acquire CinCor Pharma to strengthen cardiorenal pipeline  AstraZeneca

Soliris approved in China for the treatment of adults with refractory generalised myasthenia grav...

Soliris approved in China for the treatment of adults with refractory generalised myasthenia gravis  AstraZeneca

Acquisition of CinCor Pharma complete - AstraZeneca

Acquisition of CinCor Pharma complete  AstraZeneca

Acquisition of Icosavax Completed - AstraZeneca

Acquisition of Icosavax Completed  AstraZeneca

AstraZeneca establishes new world-class functional genomics laboratory with Medical Research Coun...

AstraZeneca establishes new world-class functional genomics laboratory with Medical Research Council and the Milner Therapeutics Institute at the University of Cambridge to accelerate drug discovery and further UK’s global genomics leadership  AstraZeneca

AstraZeneca plans $1.5 billion manufacturing facility for antibody drug conjugates (ADCs) in Sing...

AstraZeneca plans $1.5 billion manufacturing facility for antibody drug conjugates (ADCs) in Singapore  AstraZeneca

At the forefront of lung cancer treatment - AstraZeneca

At the forefront of lung cancer treatment  AstraZeneca

Information for suppliers - AstraZeneca

Information for suppliers  AstraZeneca

AstraZeneca to discover and develop self-amplifying RNA therapeutics in new collaboration with Va...

AstraZeneca to discover and develop self-amplifying RNA therapeutics in new collaboration with VaxEquity  AstraZeneca

Oncology – AstraZeneca - Redefining Cancer Care - AstraZeneca

Oncology – AstraZeneca - Redefining Cancer Care  AstraZeneca

Medicines - Our focus areas - AstraZeneca

Medicines - Our focus areas  AstraZeneca

North Korean hackers suspected of targeting vaccine maker AstraZeneca in cyberattack, Reuters rep...

North Korean hackers suspected of targeting vaccine maker AstraZeneca in cyberattack, Reuters reports  cnn.com

Graphs in Healthcare: Improving Patient Outcomes with Graph Algorithms - Neo4j

Graphs in Healthcare: Improving Patient Outcomes with Graph Algorithms  Neo4j

AstraZeneca enters commercialisation agreement with Aspen for anaesthetic medicines portfolio - A...

AstraZeneca enters commercialisation agreement with Aspen for anaesthetic medicines portfolio  AstraZeneca

AstraZeneca withdraws Covid vaccine worldwide after admitting it can cause rare blood clots - The...

AstraZeneca withdraws Covid vaccine worldwide after admitting it can cause rare blood clots  The Independent

FDA approves new medicine BRILINTA (ticagrelor) for use in the US - AstraZeneca

FDA approves new medicine BRILINTA (ticagrelor) for use in the US  AstraZeneca

Biopharma leaders unite to stand with science - AstraZeneca

Biopharma leaders unite to stand with science  AstraZeneca

Saudi Arabia - AstraZeneca

Saudi Arabia  AstraZeneca

Datopotamab deruxtecan met dual primary endpoint of progression-free survival in patients with ad...

Datopotamab deruxtecan met dual primary endpoint of progression-free survival in patients with advanced non-small cell lung cancer in TROPION-Lung01 Phase III trial  AstraZeneca

Brilinta approved in the US to reduce the risk of stroke in patients with an acute ischaemic stro...

Brilinta approved in the US to reduce the risk of stroke in patients with an acute ischaemic stroke or high-risk transient ischaemic attack  AstraZeneca

Medicines: Oncology Portfolio and Pipeline - AstraZeneca

Medicines: Oncology Portfolio and Pipeline  AstraZeneca

Vaccines and Immune Therapies - AstraZeneca

Vaccines and Immune Therapies  AstraZeneca

Nirsevimab EMA regulatory submission accepted under accelerated assessment for RSV protection in ...

Nirsevimab EMA regulatory submission accepted under accelerated assessment for RSV protection in all infants  AstraZeneca

Precision medicine - AstraZeneca

Precision medicine  AstraZeneca

FDA Advisory Committee reviewed Imfinzi for treatment of resectable non-small cell lung cancer ba...

FDA Advisory Committee reviewed Imfinzi for treatment of resectable non-small cell lung cancer based on AEGEAN Phase III trial results  AstraZeneca

Coronavirus (COVID-19) information & research hub - AstraZeneca

Coronavirus (COVID-19) information & research hub  AstraZeneca

AstraZeneca provides update on AERISTO Phase IIIb trial for Bevespi Aerosphere in chronic obstruc...

AstraZeneca provides update on AERISTO Phase IIIb trial for Bevespi Aerosphere in chronic obstructive pulmonary disease  AstraZeneca

Nirsevimab MELODY Phase III trial met primary endpoint of reducing RSV lower respiratory tract in...

Nirsevimab MELODY Phase III trial met primary endpoint of reducing RSV lower respiratory tract infections in healthy infants  AstraZeneca

ZS-9 (sodium zirconium cyclosilicate) receives positive CHMP opinion for the treatment of hyperka...

ZS-9 (sodium zirconium cyclosilicate) receives positive CHMP opinion for the treatment of hyperkalaemia  AstraZeneca

FluMist approved for self-administration in the US - AstraZeneca

FluMist approved for self-administration in the US  AstraZeneca

Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultr...

Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies  AstraZeneca

AstraZeneca announces top-line results of OSKIRA-4 Phase IIb study of fostamatinib as a monothera...

AstraZeneca announces top-line results of OSKIRA-4 Phase IIb study of fostamatinib as a monotherapy for rheumatoid arthritis  AstraZeneca

Airsupra (PT027) approved in the US for asthma - AstraZeneca

Airsupra (PT027) approved in the US for asthma  AstraZeneca

AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19 - AstraZeneca

AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19  AstraZeneca

About Our Company - AstraZeneca

About Our Company  AstraZeneca

Update on KESTREL Phase III trial of Imfinzi with or without tremelimumab in the 1st-line treatme...

Update on KESTREL Phase III trial of Imfinzi with or without tremelimumab in the 1st-line treatment of recurrent or metastatic head and neck cancer  AstraZeneca

Celgene and AstraZeneca provide update on the FUSION clinical trial programme - AstraZeneca

Celgene and AstraZeneca provide update on the FUSION clinical trial programme  AstraZeneca

AZD1222 Oxford Phase III trials interim analysis results published in The Lancet - AstraZeneca

AZD1222 Oxford Phase III trials interim analysis results published in The Lancet  AstraZeneca

AstraZeneca and Bristol-Myers Squibb announce US FDA approval of FARXIGA™ (dapagliflozin) - Astra...

AstraZeneca and Bristol-Myers Squibb announce US FDA approval of FARXIGA™ (dapagliflozin)  AstraZeneca